MyBlueDots

DENVER–(BUSINESS WIRE)–TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today the publication of research titled, “Pressure Enabled Drug Delivery (PEDD) Significantly Increases Intraarterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Mode

CHICAGO–(BUSINESS WIRE)–Press Ganey, the leading provider of experience measurement, data analytics, and insights for health systems and health plans, has released its latest research report, “Health Plan Member Experience in 2024.” This report highlights critical areas for improvement in member experience, drawing on regulatory, voice-of-the-customer, and Press Ganey’s patient experience data. The findings underscore the pressing need for health plans to address barriers to higher member sat

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

ANDOVER, Mass. & HAIFA, Israel–(BUSINESS WIRE)– #AMR–These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies.

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

CHAPEL HILL, N.C.–(BUSINESS WIRE)–Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event:   J.P. M

SAN MATEO, Calif.–(BUSINESS WIRE)–Mendaera Inc., a healthcare technology company creating a first-of-its-kind handheld robotic platform to revolutionize the delivery of prevalent interventional procedures, today announced the appointment of Eric Davidson as its first Chief Commercial Officer (CCO). Davidson will lead commercialization efforts as the company prepares for market entry with its novel robotic technologies. Davidson joins Mendaera with more than two decades of leadership in medica